The previous reclassification of the myeloid and lymphoid neoplasms took place in 2008. The classification revision in 2016 incorporated new genetic information into morphologic and immunophenotypic characterizations.
The implications of these changes are better diagnostic, prognostic and treatment options.
Not all of the cases in this course deal with the reclassifications, although several do at least incorporate some new criteria and genetic information.
The following two pages will give a very brief summary of the highlights of the changes in the WHO classification system, followed by four cases dealing with familiar and less familiar hematologic malignancies.
